Navigation Links
Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
Date:8/4/2009

NEW YORK, Aug. 4 /PRNewswire-FirstCall / -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that the Company and Alfa Wassermann S.p.A. have settled a dispute over issues arising from the terminated license agreement for Sulonex (sulodexide). Under the terms of the settlement agreement, Alfa Wassermann is paying Keryx US$3,500,000 (of which US$2,750,000 has already been received by Keryx and $750,000 is to be paid to Keryx on or before July 30, 2010), and Keryx shall deliver to Alfa Wassermann all of its data, information and other intellectual property related to Sulonex.

Ron Bentsur, Chief Executive Officer of Keryx, stated, "We are pleased that this matter has been resolved in a manner that we believe serves the best interests of the Keryx shareholders. This settlement provides us with additional non-dilutive cash to move our compounds into Phase 3 trials."

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex((TM)) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. Keryx is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in numerou
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
2. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
3. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
5. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
6. Keryx Biopharmaceuticals Receives Nasdaq Notification
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
8. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... time in half, but use in humans is still far ... improve on nature, researchers have built and tested synthetic versions ... trauma or other cases where blood just won,t stop flowing. ... is used in degradable stitches, which dissolve in the body," ... Case Western Reserve University, and lead author of a report ...
(Date:12/16/2009)... Neurological Stress Reduction Therapy or NSRTSM is found very effective ... such as allergies, asthma, migraines, chronic fatigue and a wide ... the country are using this holistic therapy including over 50 ... ... Minneapolis, MN (Vocus) December 14, 2009 -- BioVeda ...
(Date:12/16/2009)... report finds , , WEDNESDAY, Dec. 16 (HealthDay News) -- ... million Americans of all ages -- or 15.1 percent ... to new National Health Interview Survey statistics released Wednesday. ... all ages had been uninsured for at least part ... million (10.6 percent) had been uninsured for more than ...
(Date:12/16/2009)... 16 OrthoAccel Technologies, Inc., developers of ... acceleration device to enhance orthodontics, announced Alison Davies ... UK. Ms. Davies has spent the last ... dental industry, most recently for nine years as ... makers of Invisalign . ,, ...
(Date:12/16/2009)... Dec. 16 New research published ... compounds in pistachios, and molecules present in ... oil decreases levels of an inflammatory marker ... repeats 2). Inflammation is a complex biological ... or irritants, and it underlies functional changes ...
Breaking Medicine News(10 mins):Health News:Synthetic Platelets Put the Brakes on Blood Loss 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 2Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 4Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 5Health News:Over 45 Million Americans Now Lack Health Insurance 2Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 2Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 3Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 4Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 2Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 3
... Contaminated ... Toys, ... lead detection kit, today warned parents to,examine their children,s Easter toys for ... holiday toys,purchased randomly at retail stores contained dangerous levels of the toxic,element., ...
... increase in personal problems among adolescents with persistent sleeplessness, ... Science Center at Houston say they have completed the ... insomnia on 11 to 17 year olds. More than ... more symptoms of insomnia and almost half of these ...
... says single use lens is healthy contact lens option for ... Pair Certificate* ... Lenses, JACKSONVILLE, Fla., March 21 For many of ... as itching, tearing, and redness caused by contact lens wear, ...
... & 2010 Will Top 20% Changes Threaten Beneficiary ... ... 20 Leaders in the home,oxygen community today expressed concern over ... to Medicare,s competitive bidding program for the home oxygen therapy,benefit., ...
... National Academy of Elder Law,Attorneys, or NAELA, is ... help protect seniors. A NAELA survey found that ... experienced elder abuse -- whether,financial, physical or emotional ... Listen to this report from NAELA at:, http://media.medialink.com/WebNR.aspx?story=34838 ...
... (ACP) has received unrestricted grants of nearly $50,000 each ... improvement tools to support internal medicine practice changes around ... patient-centered medical home, in coordination with the other components ... of health care," says John Tooker, MD, MBA, FACP, ...
Other Medicine News:Health News:Adolescents with chronic insomnia report 'twofold to fivefold' increase in personal problems 2Health News:Relief "In Sight" for Allergy Sufferers 2Health News:Relief "In Sight" for Allergy Sufferers 3Health News:Home Oxygen Leaders Warn That Competitive Bidding Program Reductions Combined with Other Pending and Proposed Cuts Are 'Unsustainable and Unpredictable' 2Health News:ACP to develop quality improvement tools to support internal medicine practice changes 2
(Date:12/16/2009)... PHILADELPHIA, Dec. 16 AVAX Technologies, Inc. ... announced that it recently closed a bridge loan ... Note and Warrant Purchase Agreement (the "Agreement") with ... the Agreement, the Company sold a convertible promissory ... principal amount of US$1,400,000, and issued a warrant ...
(Date:12/16/2009)... RealMed has been ranked the #1 Claims ... Top 20 Best in KLAS Awards: Software ... a dynamic revenue cycle management solution providing ... providers and all payers. KLAS ... vendor performance measurement in the software, professional ...
(Date:12/16/2009)... Medical Technologies, Inc. today announced that its fully ... and interoperability solution, Prime Suite® 2011, won ... 2009 Top 20 Best in KLAS Awards: ... For practices having between six and 25 physicians, ... KLAS in ambulatory EMR for the fourth consecutive ...
Breaking Medicine Technology:AVAX Technologies, Inc. Closes Bridge Financing 2AVAX Technologies, Inc. Closes Bridge Financing 3AVAX Technologies, Inc. Closes Bridge Financing 4RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 2Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 4The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders 3B Judge Orders Incumbent Board to Remain In Place Unti 47549 1The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders 3B Judge Orders Incumbent Board to Remain In Place Unti 47549 2The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders 3B Judge Orders Incumbent Board to Remain In Place Unti 47549 3Swine Flu Now Reported in All 50 States 47547 1Swine Flu Now Reported in All 50 States 47547 2Swine Flu Now Reported in All 50 States 47547 3Swine Flu Now Reported in All 50 States 47547 4Swine Flu Now Reported in All 50 States 47547 5Swine Flu Now Reported in All 50 States 47547 6Swine Flu Now Reported in All 50 States 47547 7Swine Flu Now Reported in All 50 States 47547 8Swine Flu Now Reported in All 50 States 47547 9Swine Flu Now Reported in All 50 States 47547 10Swine Flu Now Reported in All 50 States 47547 11Research Finds New Crop of Breast Cancer Genes 47543 1Research Finds New Crop of Breast Cancer Genes 47543 2
... WEST HAVEN, Conn.--(BUSINESS WIRE)--May 14, 2007 - NanoViricides,Inc. ... recent,animal studies against rabies that were presented along ... Clade 2 H5N1 virus at,the 23rd Annual Symposium ... Tampa, FL, on Wednesday, May 2. (Pan American ...
... Perception and Symptom Severity; New,Resources for Patients, Parents, ... survey,released today by the National Consumers League shows ... these days. Four in,ten asthma sufferers understand asthma ... more recent the diagnosis, the less,knowledgeable adult patients ...
Other Medicine Technology:Global Rabies Treatment May be Possible with NanoViricides Drugs 2New Survey Finds Troubling Data on American Asthma Sufferers 2New Survey Finds Troubling Data on American Asthma Sufferers 3New Survey Finds Troubling Data on American Asthma Sufferers 4New Survey Finds Troubling Data on American Asthma Sufferers 5New Survey Finds Troubling Data on American Asthma Sufferers 6
... It is powerful, lightweight, ... comfortable, soft, durable foam ... pad, covered by machine ... Flexible headband easily adjusts ...
Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost....
View Mex-3 is designed for out-patient surgery, hospital rounds and house calls....
It provides excellent illumination from an inexpensive platform and is mounted on the comfortable UltraLite headband....
Medicine Products: